MedTrace Logo

Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas

NCT03478462 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-03-18

No results posted yet for this study

Summary

The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain tumors for which there are no standard treatment options with curative potential.

Conditions

  • Pediatric Solid Tumor
  • Pediatric Lymphoma
  • Pediatric Brain Tumor
  • DIPG
  • Neuroblastoma
  • Ewing Sarcoma
  • Rhabdomyosarcoma
  • Osteosarcoma

Interventions

DRUG

CLR 131

IV dose of CLR 131, increased/decreased by dose level; single or fractionated dose

Sponsors & Collaborators

  • Cellectar Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Jarrod Longcor · Cellectar Biosciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-30
Primary Completion
2026-08-25
Completion
2027-02-25
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03478462 on ClinicalTrials.gov